Uncomplicating the futureSM
 
Search

Healthcare Professionals

    Print page  

How SEPRAFILM® Adhesion Barrier Compares

SEPRAFILM is a site-specific adhesion barrier that stays in place without sutures, protecting the underlying viscera during the critical seven-day healing period. Since its introduction in 1996, more than a million patients have received SEPRAFILM; it's the most widely used adhesion barrier.1 SEPRAFILM is:

  • Is proven effective in fields with incomplete hemostasis4 
  • Can be layered/is not limited to single layer use
  • Sheets can be applied around adjacent tissues and structures
  • Is the only adhesion barrier shown to reduce the incidence of adhesive small bowel obstruction requiring reoperation2
  • The most widely evaluated adhesion barrier1 studied in open procedures including colorectal resection, IPAA, C-section, radical pelvic surgery, myomectomy, and other surgeries1
  • The only adhesion barrier indicated for both abdominal and pelvic laparotomy
undefined

Get the facts on SEPRAFILM and other adhesion barriers:


1. Data on File, Genzyme Corporation
 
1. Data on File, Genzyme Corporation
 
1. Data on File, Genzyme Corporation
 
2. Fazio VW, Cohen Z, Fleshman JW, et al. Reduction in adhesive small-bowel obstruction by Seprafilm Adhesion Barrier after intestinal resection. Dis Colon Rectum. 2005;49:1-11.
 
4. Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Fert Steril 1996; 66(6);904-910.
 

 

Surgeons discuss
adhesions and their potential impact on patients
Aimee's Story
See what patients say about SEPRAFILM
 

Indication

Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy.

Important Safety Information

Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm has not been established in combination with other adhesion prevention products and/or in surgical procedures not within the abdominopelvic cavity. The safety and effectiveness of Seprafilm has also not been evaluated in cases of pregnancy, malignancy, or frank infection. The type and frequency of adverse events reported are consistent with events typically seen following abdominopelvic surgery when used as directed.

Please see full prescribing information.

Terms and Conditions of Use | Privacy Policy | Contact Us | This site is intended for United States residents only © 2002-2010 Genzyme Corporation. All rights reserved. Seprafilm and Genzyme are registered trademarks of Genzyme Corporation. genzyme logo